Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence.
The motivation to maintain nicotine self-administration and dependence may involve alterations in glutamatergic neurotransmission. Metabotropic glutamate (mGlu) 2/3 receptors regulate glutamate and dopamine release in the ventral tegmental area (VTA) and the nucleus accumbens (NAc) shell, two brain areas critically involved in reward and motivational processes. We found that acute systemic, as well as intra-VTA or intra-NAc, administration of the mGlu2/3 receptor agonist LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] decreased nicotine, but not food, self-administration in rats. In addition, nicotine self-administration downregulated mGlu2/3 receptor function in corticolimbic rat brain sites including the VTA and the NAc, demonstrated by decreased coupling of mGlu2/3 receptors to G-proteins in the [35S]GTPgammaS binding assay. Furthermore, repeated treatment with LY379268 reduced nicotine self-administration at the beginning of a 14 d treatment period; however, the number of nicotine infusions earned gradually returned to baseline levels, indicating tolerance to the effects of repeated LY379268 treatment. Finally, LY379268 administration decreased both cue-induced reinstatement of nicotine- and food-seeking behavior. Together, these findings indicate an important role for mGlu2/3 receptors in the posterior VTA and the NAc shell in the mediation of the rewarding effects of nicotine and potentially in cue-induced nicotine-seeking behavior.
Liechti
Matthias E
ME
Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Lhuillier
Loic
L
Kaupmann
Klemens
K
Markou
Athina
A
D000596:Amino Acids / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D003463:Cues; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D005518:Food Preferences / Q000502:physiology / Q000523:psychology; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000493:pharmacokinetics; D008297:Male; D009538:Nicotine / Q000008:administration & dosage; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000502:physiology*; D012054:Reinforcement, Psychology; D012646:Self Administration / Q000379:methods; D014029:Tobacco Use Disorder / Q000473:pathology / Q000503:physiopathology / Q000523:psychology; D017557:Ventral Tegmental Area / Q000187:drug effects / Q000378:metabolism*
D000596:Amino Acids; D019086:Bridged Bicyclo Compounds, Heterocyclic; D018690:Excitatory Amino Acid Agonists; C118218:LY 379268; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D009538:Nicotine
J Neurosci. 1998 Sep 15;18(18):7502-10
9736668
Annu Rev Pharmacol Toxicol. 1997;37:205-37
9131252
J Pharmacol Exp Ther. 2002 Nov;303(2):608-15
12388642
J Neurochem. 2000 Sep;75(3):889-907
10936169
J Pharmacol Exp Ther. 1999 Apr;289(1):412-6
10087032
J Pharmacol Exp Ther. 2003 Sep;306(3):1068-76
12805481
Neuropharmacology. 1999 Oct;38(10):1431-76
10530808
J Comp Neurol. 2005 Jun 20;487(1):15-27
15861463
J Pharmacol Exp Ther. 2006 Aug;318(2):922-31
16675638
Am J Psychiatry. 2005 Aug;162(8):1403-13
16055761
Curr Opin Pharmacol. 2004 Feb;4(1):23-9
15018835
J Neurosci. 2003 Apr 15;23(8):3531-7
12716962
Neuron. 2000 Aug;27(2):349-57
10985354
J Neurosci. 2002 Aug 15;22(16):7225-33
12177217
J Pharmacol Exp Ther. 1999 Oct;291(1):161-70
10490900
Neurosci Lett. 2006 Jan 30;393(2-3):127-30
16233956
Neuroscience. 2001;106(3):481-503
11591452
Synapse. 2000 Dec 15;38(4):375-83
11044884
Behav Brain Res. 2006 Oct 2;173(1):148-52
16834996
J Neurosci. 2002 May 1;22(9):3338-41
11978809
Eur J Pharmacol. 2007 Jan 12;554(2-3):164-74
17113075
J Pharmacol Exp Ther. 2002 Jan;300(1):162-71
11752112
J Comp Neurol. 1993 Sep 8;335(2):252-66
8227517
Neuropsychopharmacology. 2006 Oct;31(10):2197-209
16341024
Psychopharmacology (Berl). 2006 Mar;184(3-4):417-25
16163522
J Neurosci. 2005 Jul 6;25(27):6389-93
16000629
J Neurosci. 2006 Jan 18;26(3):723-30
16421292
J Neurosci. 2004 Nov 24;24(47):10726-30
15564590
Psychopharmacology (Berl). 2006 Mar;184(3-4):435-46
16397746
Psychopharmacology (Berl). 2001 Mar;154(3):311-8
11351938
J Neurosci Methods. 1980 Dec;3(2):129-49
6110810
J Neurosci. 1996 May 1;16(9):3112-22
8622141
J Neurosci. 2004 May 19;24(20):4723-7
15152032
Behav Brain Res. 2006 Aug 10;171(2):207-15
16678921
Eur J Pharmacol. 2000 Jul 21;400(2-3):221-4
10988337
J Neurosci. 1996 Feb 15;16(4):1550-60
8778304
Neuropharmacology. 2005;49 Suppl 1:167-78
16023685
Neuroscience. 1993 Apr;53(4):1009-18
8389425
Neuropharmacology. 2004 Jul;47(1):1-8
15165829
Psychopharmacology (Berl). 1989;99(4):473-8
2594913
Psychopharmacology (Berl). 2006 Jun;186(2):143-9
16703399
Eur J Neurosci. 2005 Jan;21(1):295-300
15654869
J Neurosci. 2006 Sep 27;26(39):9967-74
17005860
Neuropsychopharmacology. 2007 Jan;32(1):103-9
16452988
J Neurophysiol. 2000 Aug;84(2):759-70
10938303
Brain Res Brain Res Rev. 1993 Jan-Apr;18(1):75-113
8096779
Neuropsychopharmacology. 2000 Sep;23(3):335-44
10942857
Neuropsychopharmacology. 2007 Mar;32(3):710-8
16794568
Eur J Neurosci. 2001 Dec;14(11):1843-55
11860480
Nat Neurosci. 2003 Jul;6(7):743-9
12778052
Neuroreport. 2005 Jun 21;16(9):1013-6
15931079
Neuropsychopharmacology. 2005 Jan;30(1):119-28
15266350
J Med Chem. 1999 Mar 25;42(6):1027-40
10090786
J Neurosci. 2000 Aug 1;20(15):RC89
10899176
Eur J Pharmacol. 2005 Dec 28;528(1-3):110-8
16324694
Physiol Behav. 2002 Dec;77(4-5):683-7
12527019
Psychopharmacology (Berl). 2000 Apr;149(3):217-24
10823401
Biol Psychiatry. 2007 Jan 1;61(1):17-22
16876138